Rezolute (RZLT) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Rezolute is scheduled to announce its Q4 2025 earnings on September 18th, with analysts expecting a loss of ($0.22) per share.
• Rezolute's stock recently opened at $8.10, with a market cap of $704.70 million and a PE ratio of -7.04.
• Insider buying activity includes Director Young-Jin Kim purchasing 1,230,769 shares, increasing their ownership by 17.11% and totaling nearly $4 million.

Rezolute (NASDAQ:RZLT - Get Free Report) is projected to announce its Q4 2025 results before the market opens on Thursday, September 18th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Investors can check the company's upcoming Q4 2025 earningsummary page for the latest details on the call scheduled for Friday, September 26, 2025 at 4:00 PM ET.

Rezolute Trading Down 2.9%

NASDAQ:RZLT traded down $0.22 during mid-day trading on Monday, reaching $7.47. 982,666 shares of the stock were exchanged, compared to its average volume of 825,375. The business has a fifty day moving average price of $6.41 and a 200 day moving average price of $4.63. The firm has a market capitalization of $649.89 million, a PE ratio of -6.50 and a beta of 0.02. Rezolute has a 1-year low of $2.21 and a 1-year high of $8.34.

Institutional Investors Weigh In On Rezolute

Several institutional investors and hedge funds have recently added to or reduced their stakes in RZLT. BNP Paribas Financial Markets acquired a new stake in Rezolute in the 2nd quarter worth approximately $25,000. Legal & General Group Plc acquired a new stake in Rezolute in the 2nd quarter worth approximately $32,000. Raymond James Financial Inc. acquired a new stake in Rezolute in the 2nd quarter worth approximately $46,000. New York State Common Retirement Fund acquired a new stake in Rezolute in the 2nd quarter worth approximately $104,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Rezolute in the 2nd quarter worth approximately $106,000. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on RZLT shares. Wall Street Zen lowered Rezolute from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and set a $14.00 target price on shares of Rezolute in a report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company's stock. According to MarketBeat, Rezolute presently has an average rating of "Buy" and an average target price of $11.67.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.